ライフサイエンスコーパス: cell count

1 tween participants in strata of baseline CD4 cell count.

2 IV-1) RNA <50 copies/mL and change in CD4+ T-cell count.

3 on gender distribution, viral load, and CD4 cell count.

4 ecreased appetite, and decreased white blood cell count.

5 ecurrent viral infections and reduced CD8+ T cell count.

6 at the time of infection and baseline CD4+ T-cell count.

7 etroviral therapy (cART) irrespective of CD4 cell count.

8 Prevalences were adjusted for age and CD4 cell count.

9 ut differed in terms of myeloid and lymphoid cell counts.

10 asing platelet counts, and lower white blood cell counts.

11 n antiretroviral therapy (cART), at high CD4 cell counts.

12 likely to normalize in those with low CD4+ T cell counts.

13 troviral therapy (ART) with high pre-ART CD4 cell counts.

14 symptoms and increased myeloid and CD4(+) T-cell counts.

15 eolin, dose-dependently increased osteoblast cell counts.

16 le LGCs numbers and decreased dead/apoptotic cell counts.

17 ning (p=5.9e-3), after adjusting for age and cell counts.

18 ell signatures as well as activated CD4(+) T cell counts.

19 s normal CD4(+) but lower than normal CD8(+) cell counts.

20 ubunit C storage, astrogliosis, and neuronal cell counts.

21 g HIV co-infected individuals with low CD4 T-cell counts.

22 linical outcomes of body weight and CD4(+) T cell counts.

23 All three regimens improved patients' CD4 cell counts.

24 and investigated the aetiology of low CD4 T-cell counts.

25 nts regarding preservation injury and goblet cells count.

26 diagnostic platform technology for CD4(+) T cell counting.

27 les, but not to zygotic genome activation or cell counting.

28 muL, 1.61 to 2.39; p<0.0001), decreased CD4 cell count (0.53 per 5 square-root cells per muL, 0.35 t

29 unit, 0.56 to 0.92; p=0.0078), increased CD8 cell count (1.51 per 5 square-root cells, 1.11 to 2.06;

30 e TdT(+) cells from TdT(-) cells even at low cell counts (~100 cells).

31 , detectable HIV RNA (19; 9-31), and low CD4 cell count (13%; 4-21).

32 severe COVID-19 had higher peak white blood cell counts (15.8 vs 7 x 10(3) /uL, P = .019), C-reactiv

33 [5%] vs 17 [7%]), and decreased white blood cell count (18 [7%] vs nine [4%]).

34 , 551-1210] cells/mm; P < 0.0001) and CD4+ T cell count (29 cells/mm [IQR, 1.3-116.0] vs 325.5 cells/

35 CHM regimens users had baseline CD4 cell counts (380.11 +/- 240.59 cell/muL), approximately

36 h a median age at switch of 50 years, CD4+ T-cell count 512 cells/muL, and BMI 26.4 kg/m2.

37 98.3% on antiretroviral therapy, median CD4+ cell count 527 cells/mm 3, 86.6% with HIV-1 RNA < 50 cop

38 meters squared) was 25.8, and the median CD4 cell count 620/uL.

39 31 [42%] vs 28 [39%]), decreased white blood cell count (8 [11%] vs 5 [7%]), and hypophosphataemia (3

40 ciated with a 29% lower baseline white blood cell count (95% confidence interval [CI], -7% to -46%; P

41 Cerebrospinal fluid testing showed normal cell counts, a negative result on reverse-transcription

42 function, and various biochemistry and blood cell count abnormalities.

43 er levels of C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin

44 er levels of C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin

45 or demographic factors, baseline HIV RNA/CD4 cell counts, AIDS defining events and the type of InSTI.

46 detectable HIV RNA, and those with lower CD4 cell counts (all P < .05).

47 is resulted in lower of Ag-specific CD4(+) T cell count and Ab titers in mice.

48 White blood cell count and C-reactive protein level were elevated, a

49 In adjusted analyses, entry CD4 cell count and CD4/CD8 ratio were associated with GBD re

50 levels were inversely associated with CD4 T-cell count and CD4:CD8 ratio, while positively correlate

51 Sputum differential cell count and IS supernatant (ISS) levels of prostanoid

52 betaDG correlated negatively with CD4 T-cell count and positively with time to ART initiation, v

53 try, intraocular pressure (IOP), endothelial cell count and postoperative complications.

54 Elevations in CSF white-cell count and protein were reported as adverse events i

55 s and confirmed to account for the different cell count and technical variability.

56 was associated with total airway epithelial cell count and thickness.

57 Cell counting and DNA extraction showed a diverse but lo

58 low-cost, label-free, and real-time on-chip cell counting and quantifying method for sorted/separate

59 BA pool increases colonic RORgamma(+ )T(reg) cell counts and ameliorates host susceptibility to infla

60 This lead us to compare CD4+ and CD8+ T-cell counts and CD4+/CD8+ ratios between HIV-negative MS

61 Primary endpoints were changes in CD4 T-cell counts and CD4/CD8 ratio from baseline to week 48 a

62 The analyses of CD4 cell counts and CD4/CD8 ratios may provide valuable insi

63 toma and is characterized by decreased CD4 T-cell counts and downregulation of major histocompatibili

64 s consistently associated with reduced CD4 T cell counts and elevated levels of T cell activation and

65 severe thrombocytopenia, reduced white blood cell counts and high fever with 93% mortality rate.

66 ociations between higher relative FOXP3(+) T-cell counts and increased risks of colorectal and breast

67 lysis of the humoral system shows that blood cell counts and inflammatory markers are differentially

68 ity of patients who maintain normal CD4(+) T-cell counts and low or undetectable viral loads for deca

69 pha exhibited a more pronounced elevation of cell counts and protein content in bronchoalveolar lavag

70 ncology to psychiatry, can lower white blood cell counts and thus access to these treatments can be r

71 of monocytes to lymphocytes, activated CD4 T cell count, and a blood RNA signature could be correlate

72 es were assessed for HIV RNA viral load, CD4 cell count, and antiretroviral drug-resistant mutations.

73 rate, virus clearance, viral load, CD4(+) T cell count, and CD4(+) T cell loss in SIV-infected macaq

74 Age, white cell count, and day of illness at study enrollment were

75 and phenotype, early thymic progenitor (ETP) cell count, and expression of FOXN1 target genes (Ccl25,

76 r changes, contrast sensitivity, endothelial cell count, and possible adverse events were assessed at

77 viral therapy (ART) at a higher vs lower CD4 cell count, and the longer-term harms associated with cu

78 nterior chamber depth and angle, endothelial cell count, and visual acuity did not change in this coh

79 against viremia, fever, elevated white blood cell counts, and CHIKF-associated cytokine changes after

80 was associated with older ages, lower white cell counts, and earlier stages of illness at presentati

81 combination antiretroviral therapy use, CD4 cell counts, and HIV RNA.

82 , broncho-alveolar lavage protein levels and cell counts, and IL-6 and IP-10 concentrations.

83 up plasma viremia, peripheral blood CD4(+) T cell counts, and lymph node and rectal tissue viral load

84 ation, complete and differential white blood cell counts, and lymphocyte subsets for 301 infants, wit

85 We examined hemoglobin, red and white blood cell counts, and platelet counts and volume in regular m

86 thymic involution, declines in peripheral T-cell counts, and reduced major histocompatibility comple

87 copies per mL, changes from baseline in CD4 cell counts, and the frequency of adverse events, advers

88 individuals, those with higher nadir CD4+ T-cell counts, and those who had received lopinavir/ritona

89 estimated glomerular filtration rate, CD4+ T-cell count, antiretroviral drug class and duration of th

90 nfection (aOR 1.14), recent high white blood cell count (aOR 1.08), and genitourinary disorder (aOR 1

91 od function with respect to a time series of cell counts, approximated by the Central Limit Theorem f

92 onor cornea age and higher donor endothelial cell count are associated with better long-term graft su

93 ng of low-abundance cells, particularly when cell counts are sample-limited and operationally difficu

94 In this study, we investigate blood cell counts as a potential mechanism linking mLOY to dis

95 gevity, neurobehavioral parameters, neuronal cell counts, astrogliosis, and diminution in brain and s

96 s (IQR 30-43), 45.4% were female, median CD4 cell count at admission was 76 cells/mul (IQR 23-206), a

97 ime with NVL, and WHO clinical stage and CD4 cell count at ART initiation, rates of excess all-cause

98 ; P = .004), while survivors had similar CD4 cell count at baseline, regardless of HTLV status.

99 nd platelet number at day 10 and white blood cell count at day 60.

100 ling defined a minimal model including white cell count at diagnosis, pretreatment cytogenetics, and

101 ethod, with balancing for circulating tumour cell count at screening, to receive 400 mg or 300 mg ola

102 ls were characterized by flow cytometry, and cell counts at different time-points were compared with

103 d not previously received ART and had CD4+ T-cell counts below 100 cells per cubic millimeter.

104 There was no difference in endothelial cell counts between CXL samples and controls (P = .21).

105 f the year, whereas results from microscopic cell counts, biovolume analysis and metatranscriptomics

106 use serum and significantly increasing blood cell counts, BM hematopoietic cellularity and stem and p

107 wed accelerated recovery in peripheral blood cell counts, bone marrow colony forming units, sternal c

108 was associated with older age and lower CD4 cell count (both P < .05).

109 Hair cell counts (both inner and outer) as well as frequency

110 ificant difference in any of the white blood cell counts by diet group.

111 aist circumference), and immune (white blood cell count, C-reactive protein) markers.

112 cent, past, cumulative, or nadir/peak CD4+ T-cell count (CD4) and/or HIV-1 RNA level (HIV RNA) best p

113 ntry regimen, duration of ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated

114 to placebo-treated subjects, in mean CD4+ T-cell count change (278 vs 250 cells/muL, P = .474) or CD

115 changes in weight (all children) and CD4+ T-cell counts (children with HIV only).

116 ors on the causal pathway (most notably, CD4 cell count, clinical signs of advanced HIV, and poor fun

117 2%; 17.2-46.1) of 43; and circulating tumour cell count conversion was achieved in 15 (53.6%; 33.9-72

118 ut robustly-correlated with anterior chamber cell count (correlation coefficient range 0.41-0.81).

119 gth increased red blood cell and white blood cell counts, decreased mean corpuscular hemoglobinand me

120 iciency virus (HIV)-positive adults, low CD4 cell counts despite fully suppressed HIV-1 RNA on antire

121 er in those with comorbidities and lower CD4 cell counts, despite HIV viral suppression.

122 T cells and B cells, and normalization of NK-cell counts during a median follow-up of 16 months.

123 ive spherical equivalent (MRSE), endothelial cell count (ECC), and corneal thickness.

124 mes measured were visual acuity, endothelial cell count (ECC), rates of secondary graft failure (SGF)

125 controls, had significantly increased immune cell counts, especially neutrophils, CD4(+) T cells, and

126 logical cancer requires complete white blood cell count, followed by flow cytometry with multiple mar

127 see text]=1.47, 95% CI 0.26, 2.67) and CD4 + cell count ([Formula: see text]= - 0.68, 95% CI - 1.10,

128 mains inherently challenging, with a limited cell count from tumor samples, to achieve potent persona

129 aseline, or conversion of circulating tumour cell count (from >=5 cells per 7.5 mL blood at baseline

130 usions, immunophenotypic groups, white blood cells count, gender or age.

131 of ART to asymptomatic individuals with CD4 cell counts greater than 500/mm3 and shows sustained red

132 ng stable antiretroviral therapy with CD4+ T-cell count >100 cells/mm3, and with low to moderate card

133 tients with more severe baseline uveitis (AC cell count >25).

134 ious anterior uveitis (anterior chamber [AC] cell count >=11 cells) were randomized to EGP-437 delive

135 ature >=39 degrees C, peripheral white blood cell count >=20 000/mm3, C-reactive protein >=70.0 mg/L,

136 >=40 years old with treated HIV, with CD4+ T-cell count >=400 cells/muL and with/at increased risk fo

137 d/or recent HIV infection (patients with CD4 cell count >=500/mm3 at HIV diagnosis; (PRHI) between 20

138 nosis soon after HIV infection (ie, with CD4 cell count >=500/muL or with acute HIV infection) and us

139 9% vs 36.6%; P < .0001), and had white blood cell counts >=15 000 cells/uL (31.4% vs 21.4%; P < .0001

140 ified 333 HIV-infected patients with CD4 + T-cell-counts >= 500/ul, among them 178 met the inclusion

141 opportunistic infections, and minimum CD4 T-cell counts (>100 cells per muL for liver and >200 cells

142 up among WLHIV with higher contemporary CD4+ cell counts (>=200 cells/uL vs <200 cells/uL [cOR = 0.36

143 ociated with weight gain including lower CD4 cell count, higher HIV type 1 RNA, no injection drug use

144 changes in weight (all children) and CD4+ T cell counts (HIV-infected children only).

145 cies occur in different contexts of age, CD4 cell count, HIV control, viral co-infections, or chronic

146 eatment history, plasma HIV RNA, nadir CD4+T-cell count, HIV subtype, and country were investigated.

147 rved between microbiome diversity and CD4+ T-cell count, HIV viral load, or HIV-associated chronic lu

148 r all coinfected patients, regardless of CD4 cell count.HIV/human T-cell lymphotrophic virus type 1 c

149 on was measured based on sputum differential cell counts, IL-1beta protein levels (ELISA), and sputum

150 CD4 cell counts improved over time (Ptrend <.001) so that th

151 stics, plasma HIV RNA, nadir and current CD4 cell count in blood, current CD8 cell count in blood, es

152 current CD4 cell count in blood, current CD8 cell count in blood, estimated duration of HIV infection

153 but, surprisingly, testosterone reduced red cell count in iron-deficient mice.

154 Testosterone treatment increased red cell count in iron-replete mice, but, surprisingly, test

155 res were negatively associated with the CD4+ cell count in male children (beta: -0.13, 95% confidence

156 d using unbiased and efficient stereological cell counting in eight neocortical regions.

157 tly reduced viral loads and increased CD4+ T cell counts in blood and bronchoalveolar lavage (BAL) sa

158 d high peripheral T follicular helper (pTfh) cell counts in blood but low Tfh cell counts in lymph no

159 hanges were associated with reduced CD4(+) T cell counts in both the mesenteric lymph nodes and colon

160 UFP-exposed offspring had lower white blood cell counts in bronchoalveolar lavage fluid and less pro

161 route had high Tfh cell counts in lymph nodes but low pTfh cell counts in t

162 lper (pTfh) cell counts in blood but low Tfh cell counts in lymph nodes.

163 n of L. rhamnosus were assessed by bacterial cell counts in nasal mucosa, fecal samples, cervical lym

164 with CD4+CD38+ cell numbers and total CD4+ T cell counts in patients with a suppressed viral load.

165 of M2 macrophages, correlate with low CD4+ T cell counts in patients with suppressed viral load, rais

166 Tfh cell counts in lymph nodes but low pTfh cell counts in the blood.

167 nergic cell distribution, density, and total cell counts in the different cell-type-specific KO lines

168 type mixtures were validated against actual cell counts in whole blood samples.

169 he highest and most sustained systemic white cell count increase.

170 CD4+ cell counts increased at doses >=50 mg.

171 hromatin accessibility (MACC) assay with low-cell count input, we profile both small-scale (kilobase)

172 onth BSCVA; 3-, 6-, and 12-month endothelial cell counts; intraoperative and postoperative complicati

173 The most pronounced decrease in cell counts is observed for CD8 T-cells and VD2 gammadel

174 tes, survival time, baseline and current CD4 cell count, last HIV-1 RNA plasma viral load (pVL), and

175 performance status of 3 or less, white blood cell count less than 10 x 10(9) per L, and adequate end-

176 reased transmission risk in persons with CD4 cell counts less than 500/mm3.

177 ase and had significantly higher white blood cell counts, lower lymphocyte counts, and increased C-re

178 Before ART initiation, PTCs had higher CD4 T cell counts, lower plasma viremia, and SIV-DNA content i

179 tive serology, 22 (22.5%) had an endothelial cell count < 2000 cells/mm(2) and 6 (6.1%) are at time o

180 HIV-1 RNA >=100 000 copies/mL, 21% had CD4+ cell count <200 cells/uL, and 31% enrolled <=48 hours fr

181 omegalovirus mismatch (4 points); and CD8+ T-cell count <400 cells/muL (2 points).

182 ry post-ART initiation in patients with CD4+ cell counts <200 cells/mm3 and >=200 cells/ mm3 was 27.4

183 ads (VLs) >100,000 copies/mL and 47% had CD4 cell counts <200/mm 3.

184 lass B or C at SVR (10.71 [1.32-87.01]), CD4 cell counts <200/uL at SVR time-point (4.42 [1.49-13.15]

185 lass B or C at SVR (10.71 [1.32-87.01]), CD4 cell counts <200/uL at SVR time-point (4.42 [1.49-13.15]

186 viation, 28-40), and 17.6% had baseline CD4+ cell counts <50 cells/mm3.

187 viduals having detectable HIV RNA and CD4+ T-cell counts <500 cells/uL with HIV-negative individuals.

188 HIV and having detectable HIV RNA and CD4+ T-cell counts <500 cells/uL with individuals living withou

189 ia (ICL) is defined by persistently low CD4+ cell counts (<300 cells/muL) in the absence of a causal

190 prospective cohort of patients with AHD (CD4 cell count, <=200/mul) receiving CD4 count testing, whol

191 erum antibody levels, bronchoalveolar lavage cell counts, lung histology, lung cytokine levels, and a

192 mmon processing pipelines to produce gene-by-cell count matrices from droplet-bases scRNA-seq data, d

193 between normalization of CSF WBCs and CD4+ T cell count may indicate continued imprecision in neurosy

194 e normalization of CSF WBC counts and CD4+ T cell counts may indicate continued imprecision in neuros

195 types according to their sputum granulocytic cell count.Measurements and Main Results: In the discove

196 ing of HBECs, without influencing epithelial cell count, metabolic activity, or barrier function.

197 tive protein (n = 2), albumin (n = 2), white cell count (n = 3), neutrophils (n = 2), and platelets (

198 Despite ART-associated improvement in CD4+ T cell counts (nadir CD4 <200 cells/mm3 with >350 cells/mm

199 ral therapy-associated improvement in CD4+ T-cell counts (nadir, <200/muL; >350/muL after antiretrovi

200 usting for sex, ethnicity, hypertension, CD4 cell count, nadir CD4 <200u/L, and time since HIV diagno

201 cluded initial respiratory rate, white blood cell count, neutrophil/lymphocyte ratio, and lactate deh

202 tion raises inflammatory-related white blood cell counts (neutrophils and monocytes), thereby increas

203 rs and for high vs lower initial white blood cell count, no significant differences between TDT group

204 k of circadian rhythmicity in GR-deficient B cell counts normally associated with diurnal patterns of

205 The lower white blood cell counts observed in low and non-meat eaters, and dif

206 d group, followed by the group with a CD4+ T-cell count of >=200 cells/muL and the group with a CD4+

207 g antiretroviral therapy (ART) with a CD4+ T-cell count of <100 cells/muL were enrolled and followed

208 severely impaired in the group with a CD4+ T-cell count of <200 cells/muL.

209 >=200 cells/muL and the group with a CD4+ T-cell count of <200 cells/muL.

210 tures (age >= 1 and < 10 years), white blood cell count of <50 x109/L, lack of extramedullary leukemi

211 (normal range, 0.2-0.9 mg/L), a white blood cell count of 11.69 x10(9)/L (normal range, 4-10 x10(9)/

212 test results showed an increased white blood cell count of 13 000/muL (13 x10(9)/L) (normal range, 37

213 test results showed an increased white blood cell count of 13,000/uL (13 x 109/L) (normal range, 3700

214 es revealed leukocytosis, with a white blood cell count of 15.1 x 10(3)/uL (15.1 x 10(9)/L) (normal r

215 es revealed leukocytosis, with a white blood cell count of 15.1 x 103/muL (15.1 x 109/L) (normal rang

216 g/L (normal range, 0-10 mg/L), a white blood cell count of 24.5 x 10(9)/L (normal range, [4.0-11.0] x

217 al range, [4.0-11.0] x 10(9)/L), a red blood cell count of 3.39 x 10(12)/L (normal range, [4.5-5.5] x

218 ormal limits, including a normal white blood cell count of 6400/muL.

219 value, <8.0 mg/L [76.2 nmol/L]), and a white cell count of 7 x 10(9)/L (normal range, [4-11] x 10(9)/

220 ts who were HIV positive with a baseline CD4 cell count of less than 100 cells per uL were excluded.

221 normalized hepcidin expression and the total cell count of the bone marrow and spleen, but it had no

222 nd 32 of 97 PA 1% subjects (33.0%) had an AC cell count of zero (difference, 0.34; 95% CI, -12.94 to

223 nt was the proportion of subjects with an AC cell count of zero on day 14.

224 , p=0.94) and for each increase in nadir CD4 cell counts of 100 cells per muL, there was a 40% decrea

225 in ART group during the first 6 months, CD4 cell counts of patients in CHM group and CHM combined wi

226 interaction between PM(2.5) and white blood cell count only in the model of lung function (p=0.0003)

227 r an investigator to correctly model the CD4 cell count or disease biomarkers of a patient in the pre

228 d placebo participants were observed in CD4+ cell counts or plasma HIV-1 RNA over the first year afte

229 ting for probe correlations, data structure (cell-count or relatedness), and single-nucleotide polymo

230 ss index (BMI; P = .003), higher white blood cell count (P = .005), and higher D-dimer levels (P = .0

231 The lowest EFA group had lower median CD4 T-cell counts (P < .01) and lower proportion of patients w

232 IV-infected individuals who had lower CD4+ T-cell counts (P = .01), had higher viral loads (P < .01),

233 bacterium animalis subsp lactis BB-12 (total cell count per capsule, 1.3 x 1010 to 1.6 x 1010) (n = 1

234 nfectant byproducts) and microbiology (total cell counts, plate counts, and opportunistic pathogen ge

235 propose a unique low cost device as a blood cell counting platform.

236 croscopy, root growth kinematics, G2/M phase cell count, ploidy levels and ribosome polysome profiles

237 Blood eosinophil cell counts predicted srT2-high asthma when body mass in

238 after controlling for the most recent CD4+ T-cell count, pregnancy incidence rates in HIV-positive wo

239 ratio, BAL protein levels, BAL inflammatory cell counts, pro-inflammatory cytokines, and pulmonary f

240 te the monthly probabilities of on-ART CD4 T-cell count progression, mortality, ART dropout, and ART

241 tation-positive non-MPNs with elevated blood cell counts raise concerns of MPN underdiagnosis in the

242 (HR), 95% confidence interval (CI)] only red cell count (RCC) (p = 0.004), red cell distribution widt

243 tau PET SUVRs and both HIV loads and CD4+ T-cell counts (recent and nadir).

244 ctive CSF-VDRL, the relationship with CD4+ T cell count remained unchanged.

245 e CSF-VDRL, the relationship with the CD4+ T cell count remained unchanged.

246 Post-BMT, T-cell counts remained significantly lower compared with p

247 CD4+ T-cell counts remained stable throughout the duration of t

248 an be predicted using blood biochemistry and cell count results andthe recent advances in artificial

249 and milk samples were collected for somatic cell count (SCC) and colony forming units (CFU).

250 Galactosylceramide also increased neuronal cell counts significantly in male and female mice and te

251 city, baseline BMI, nadir and current CD4+ T-cell count, smoking, diabetes and follow-up time with su

252 r muL (Jan 1, 2016-Sept 30, 2016) to any CD4 cell count (test and treat, Oct 1, 2016-March 31, 2017).

253 advocate continued provision of baseline CD4 cell count testing in HIV care in low- and middle-income

254 d using leftover blood drawn for routine CD4 cell count testing.

255 ence for associations between mLOY and blood cell counts that should stimulate investigation of the u

256 y with suppressed HIV viremia and high CD4 T cell counts, the efficacy of conventional chemotherapies

257 taking into consideration immune status, CD4 cell counts, the presence of systemic disease, and the r

258 o 2 subgroups by forced binary clustering of cell counts: the inflamed depression subgroup (n = 81 ou

259 Mean increases from baseline in CD4+ T-cell count through 48 weeks were 195.5 cells/mm3 for DOR

260 or less or a decline in absolute neutrophil cell count to 1.0 x 109/L or less leading to a dose redu

261 defined as a decline in absolute white blood cell count to 2.5 x 109/L or less or a decline in absolu

262 ral replication and decays in their CD4(+) T-cell counts to identify potential immune and virological

263 evels of albumin and sodium, and white blood cell count, to identify metabolites that differed betwee

264 After adjustment for age, BMI, sex, CD4 cell count, triglycerides, and separately adding sCD163,

265 After adjustment for age, BMI, sex, CD4 cell count, triglycerides, and separately adding sCD163,

266 es of each CpG site, adjusting for estimated cell count using a cord blood reference, sample plate, m

267 IOP, corneal status, and endothelial cell count values were in the normal range.

268 We compare a total of ten cell-counting, viability-improvement, and lymphocyte-enr

269 to explore the influence of baseline CD4+ T-cell count, viral load, study type, previous time on com

270 ationship of mtDNA CN to HIV markers (CD4+ T-cell counts, viral load, antiretroviral therapy [ART] us

271 tive protein, plasma fibrinogen, white blood cell count, vitamin D, high-density lipoprotein choleste

272 ized cohort; the mean increase in the CD4+ T-cell count was 139 cells per cubic millimeter and 64 cel

273 The median CD4+ T cell count was 19 cells/uL (IQR 9-70) and did not differ

274 , body mass index was 25.1 kg/m2, and CD4+ T-cell count was 318 cells/muL.

275 The median CD4 T-cell count was 620/uL (interquartile range, 447-826/ u L

276 The median CD4 T-cell count was 664 cells/muL.

277 Median age was 40 years (IQR 35-48), CD4 cell count was 683 cells per muL (447-935), and body-mas

278 The highest quartile of white blood cell count was associated with lower lung function and h

279 White blood cell count was higher in the n-3 PUFA group at the fourt

280 Lower absolute CD4 + T-cell count was inversely associated with PASP which warr

281 The median initial white blood cell count was significantly higher in patients who died

282 The Methods also stated that cell counting was done using a Beckman Multisizer 3 Coul

283 on of CCL17 and CCL22 production with CD4+ T cell counts was detected.

284 h culture-negative meningitis with CSF white cell count (WCC) above 20 cells per muL were included in

285 tion monitoring (QCM-D) and microscopy-based cell counting were used to quantify DC field effects on

286 Average endothelial cell counts were 1963 cells/mm(2) in DMEK and 2113 cells

287 f ART, and nadir CD4 cell count; CD4 and CD8 cell counts were also associated with body mass index an

288 OY, detected by genotyping arrays, and blood cell counts were assessed by multivariable linear models

289 In Experiment 1, manually-obtained cell counts were compared to those detected via OCFU, IM

290 Osteoblast and inflammatory cell counts were counted on hematoxylin-eosin-stained sl

291 on, allergen-driven IL-35 levels and iT(R)35 cell counts were increased in patients receiving SLIT (a

292 Corneal endothelial cell counts were lower in eyes that underwent IOL implan

293 Total regulatory T-cell counts were lower in patients with vitiligo than in

294 er or presented earlier and with lower white cell counts were more likely to have poor platelet recov

295 Peripheral immune cell counts were used to distinguish inflamed and uninfl

296 stological signs of damage and higher goblet cells count when compared with samples without LP, regar

297 ily calculated from a routine complete blood cell count with differentials.

298 The effect was modified by CD4 cell count with protection conferred if CD4 count was <=

299 a viral load [PVL], and nadir or current CD4 cell count) with outcomes of anal high-risk HPV prevalen

300 resonance imaging (CMR) and a complete blood cell count within 24 hours before and after PCI were enr